Invitrogen™ ProcartaPlex™ Human Immune Monitoring Panel for MAGPIX, 65plex

The ProcartaPlex Human Immune Monitoring Panel for MAGPIX 65plex is a preconfigured multiplex immunoassay kit that measures 65 cytokines, chemokines, and growth factors using Luminex xMAP technology. Analyze these 65 targets simultaneously for efficient immune response profiling, biomarker discovery, and validation. This kit consists of two separate kits: a 43-plex and a 22-plex kit that have been specifically designed to be used on the MAGPIX instrument that is capable of detecting up to 50 targets simultaneously. Luminex 100 and FLEXMAP 3D users should use the Human Immune Monitoring Panel 65plex (Cat. No. EPX650-10065-901) that contains all 65 targets in a single panel. The panels (43-plex and 22-plex) are provided in a ready-to-use format with individual vials of capture and detection reagents formulated at 1X concentration, requiring less pipetting and experimental setup.

ProcartaPlex preconfigured panels are extensively tested for analyte combinability, interference, and cross-reactivity to provide the highest level of validation and precision. All ProcartaPlex panels are supplied with the necessary reagents to perform the assay.

ProcartaPlex multiplex panels are available in multiple formats across six species (human, mouse, rat, nonhuman primate, porcine, and canine).

Target list [bead region]:

• 22-plex: APRIL [52], BAFF [65], BLC (CXCL13) [15], CD30 [34], ENA-78 (CXCL5) [55], Eotaxin-2 (CCL24) [37], Eotaxin-3 (CCL26) [77], FGF-2 [75], Fractalkine (CX3CL1) [39], IL-16 [47], IL-2R (CD25) [22], IL-20 [26], I-TAC (CXCL11) [46], MCP-2 (CCL8) [18], MCP-3 (CCL7) [66], MDC (CCL22) [30], MIF [67], MIG (CXCL9) [54], TNF-RII [45], TRAIL (CD253) [29], TSLP [61], TWEAK [35]
• 43-plex: CD40L (CD154) [74], Eotaxin (CCL11) [33], Gro-alpha (CXCL1) [61], G-CSF (CSF-3) [42], GM-CSF [44], HGF [46], IFN alpha [48], IP-10 (CXCL10) [22], IFN gamma [43], IL-1 alpha [62], IL-1 beta [18], IL-2 [19], IL-3 [73], IL-4 [20], IL-5 [21], IL-6 [25], IL-7 [26], IL-8 (CXCL8) [27], IL-9 [52], IL-10 [28], IL-12p70 [34], IL-13 [35], IL-15 [65], IL-17A (CTLA-8) [36], IL-18 [66], IL-21 [72], IL-22 [76], IL-23 [63], IL-27 [14], IL-31 [37], LIF [15], M-CSF [67], MCP-1 (CCL2) [51], MIP-1 alpha (CCL3) [12], MIP-1 beta (CCL4) [47], MIP-3 alpha (CCL20) [56], MMP-1 [64], NGF beta [55], SDF-1 alpha (CXCL12) [13], SCF [39], TNF alpha [45], TNF beta [54], VEGF-A [78]

About ProcartaPlex assays for the Luminex platform

ProcartaPlex immunoassays are based on the principles of a sandwich ELISA, using two highly specific antibodies binding to different epitopes of one protein to quantitate all protein targets simultaneously using a Luminex instrument. ProcartaPlex multiplex assays require as little as 25 μL of plasma or serum, or 50 μL of cell culture supernatant, and just four hours to obtain analyzed results.

• Reproducible, reliable results—validated as a panel to the highest industry standard, including protein target combinability and cross-reactivity testing
• More results per sample—measure multiple protein targets simultaneously in a single 25–50 μL sample
• Well-established Luminex technology—highly referenced multiplexing platform for protein detection and quantitation

ProcartaPlex assays utilize Luminex xMAP (multianalyte profiling) technology for the simultaneous detection and quantitation of up to 80 protein targets in a single 25 to 50 μL sample—from plasma, serum, cell culture supernatants, and other bodily fluids.